PE20181515A1 - BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS - Google Patents
BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLSInfo
- Publication number
- PE20181515A1 PE20181515A1 PE2018001063A PE2018001063A PE20181515A1 PE 20181515 A1 PE20181515 A1 PE 20181515A1 PE 2018001063 A PE2018001063 A PE 2018001063A PE 2018001063 A PE2018001063 A PE 2018001063A PE 20181515 A1 PE20181515 A1 PE 20181515A1
- Authority
- PE
- Peru
- Prior art keywords
- wnt signaling
- tumor cells
- polypeptides
- methods
- biparatopic polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invencion proporciona polipeptidos de fijacion de reaccion cruzada con LRP5/LRP6 biparatopicos novedosos y, mas especificamente, constructos de dominio variable unico de inmunoglobulina de reaccion cruzada con LRP5/LRP6 biparatopicos novedosos que pueden inhibir las vias de senalizacion Wnt. La invencion tambien se refiere a secuencias especificas de estos polipeptidos, metodos para su fabricacion y metodos para usarlos, que incluyen metodos para el tratamiento de enfermedades, tales como cancer.The invention provides novel biparatopic LRP5 / LRP6 cross-reactive polypeptides and, more specifically, novel biparatopic LRP5 / LRP6 cross-reactive immunoglobulin single variable domain constructs that can inhibit Wnt signaling pathways. The invention also relates to specific sequences of these polypeptides, methods for their manufacture and methods for using them, including methods for the treatment of diseases, such as cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15197999 | 2015-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181515A1 true PE20181515A1 (en) | 2018-09-21 |
Family
ID=54782606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018001063A PE20181515A1 (en) | 2015-12-04 | 2016-12-02 | BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS |
Country Status (34)
Country | Link |
---|---|
US (2) | US10597449B2 (en) |
EP (2) | EP3797790A1 (en) |
JP (2) | JP6728355B2 (en) |
KR (1) | KR20180081825A (en) |
CN (1) | CN108289943B (en) |
AR (1) | AR106949A1 (en) |
AU (1) | AU2016363787B2 (en) |
BR (1) | BR112018010537A2 (en) |
CA (1) | CA3006235A1 (en) |
CL (1) | CL2018001384A1 (en) |
CO (1) | CO2018005680A2 (en) |
CY (1) | CY1123454T1 (en) |
DK (1) | DK3383425T3 (en) |
EA (1) | EA201891331A1 (en) |
ES (1) | ES2821099T3 (en) |
HK (1) | HK1255725A1 (en) |
HR (1) | HRP20201528T1 (en) |
HU (1) | HUE051777T2 (en) |
IL (1) | IL259119B (en) |
LT (1) | LT3383425T (en) |
MA (2) | MA43368B1 (en) |
MX (1) | MX2018006760A (en) |
MY (1) | MY200933A (en) |
PE (1) | PE20181515A1 (en) |
PH (1) | PH12018501155A1 (en) |
PL (1) | PL3383425T3 (en) |
PT (1) | PT3383425T (en) |
RS (1) | RS60823B1 (en) |
SA (1) | SA518391728B1 (en) |
SG (1) | SG11201804510PA (en) |
SI (1) | SI3383425T1 (en) |
TW (1) | TWI734719B (en) |
UA (1) | UA122079C2 (en) |
WO (1) | WO2017093478A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2968742T3 (en) | 2012-02-28 | 2024-05-13 | Novartis Ag | Selection of cancer patients for administration of Wnt signaling inhibitors using Rnf43 mutational status |
EA201891165A1 (en) | 2015-11-18 | 2018-11-30 | Мерк Шарп И Доум Корп. | MOLECULES BINDING PD1 AND / OR LAG3 |
CA3006235A1 (en) | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
AU2018276409A1 (en) * | 2017-05-31 | 2019-10-31 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
JP2020530454A (en) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Platform for producing safe cell therapies |
US11365250B2 (en) * | 2017-11-29 | 2022-06-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cancer therapy |
WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
EP3947455A1 (en) | 2019-03-29 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
US11578129B2 (en) | 2019-03-29 | 2023-02-14 | Boehringer Ingelheim International Gmbh | LRP5 and PD-1 antagonist anticancer combination therapy |
CN114040926A (en) | 2019-05-04 | 2022-02-11 | 印希比股份有限公司 | Polypeptide binding to CD123 and uses thereof |
WO2020227481A1 (en) * | 2019-05-08 | 2020-11-12 | Bluebird Bio, Inc. | Cd123 targeted immunotherapies |
MX2022001947A (en) * | 2019-08-14 | 2022-06-14 | Modmab Therapeutics Inc | Antibodies that bind to lrp5 proteins and methods of use. |
WO2021026666A1 (en) * | 2019-08-14 | 2021-02-18 | Modmab Therapeutics Inc. | Antibodies that bind to lrp6 proteins and methods of use |
CN112794914B (en) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | ALK nano antibody developed based on phage display technology and application thereof |
WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
US20220348659A1 (en) * | 2021-03-24 | 2022-11-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
JPWO2023286854A1 (en) * | 2021-07-16 | 2023-01-19 | ||
CN116375851B (en) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | Nanometer antibody of anti-avian influenza virus NP protein, preparation method and application thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE427968T1 (en) | 1992-08-21 | 2009-04-15 | Univ Bruxelles | IMMUNOGLOBULINS WITHOUT LIGHT CHAIN |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
US6528054B1 (en) * | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
EP1276756A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusion proteins |
JP4303105B2 (en) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | Dual specific ligands and their use |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
JP5113523B2 (en) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | Polypeptides comprising nanoantibodies against amyloid-β and nanoantibodies TM for the treatment of neurodegenerative diseases such as Alzheimer's disease |
DK2949668T3 (en) | 2005-05-18 | 2019-11-11 | Ablynx Nv | IMPROVED NANOBODIES TM AGAINST TUMOR CANCER FACTOR-ALFA |
US7622267B2 (en) * | 2006-05-30 | 2009-11-24 | Van Andel Research Institute | Low-density lipoprotein receptor 6 (LRP6) as a mammary stem cell marker and related methods |
WO2007142298A1 (en) | 2006-06-08 | 2007-12-13 | Nsk Ltd. | Shell needle bearing with seal ring and its manufacturing method |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
CN100428934C (en) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | Application of cumarin kind compound in preparation of medicine for inducing nerve stem cell orienting differentiation |
US20100113339A1 (en) | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
JP2010511397A (en) | 2006-12-05 | 2010-04-15 | アブリンクス エン.ヴェー. | Peptides that can bind to serum proteins |
BRPI0820327A2 (en) | 2007-11-02 | 2020-10-06 | Novartis Ag | molecules and methods for protein modulation related to low density 6 lipoprotein receptor (lrp6) |
CA2717015A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
JP2011516603A (en) | 2008-04-17 | 2011-05-26 | アブリンクス エン.ヴェー. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides containing them |
US8661423B2 (en) | 2009-05-01 | 2014-02-25 | Telcordia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
BR112012017051A2 (en) | 2009-12-23 | 2017-12-05 | Esbatech Alcon Biomed Res Unit | method to decrease immunogenicity |
JP2013518853A (en) | 2010-02-05 | 2013-05-23 | アブリンクス エン.ヴェー. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides containing the same |
MA34025B1 (en) | 2010-03-03 | 2013-02-01 | Boehringer Ingelheim Int | POLYPEPTIDES BINDING TO BETA-A |
BR112012022044A2 (en) * | 2010-03-24 | 2020-08-25 | Genentech Inc | ''antibody, immunoconjugate, pharmaceutical formulation, antibody use, treatment method, isolated bispecific antibody and host cell''. |
BR112012028326A2 (en) * | 2010-05-06 | 2017-03-21 | Novartis Ag | isolated multivalent antibody, isolated biparatopic antibodies, nucleic acid, vector, pharmaceutical composition, method of obtaining said antibodies and use thereof |
ES2949159T3 (en) | 2010-05-06 | 2023-09-26 | Novartis Ag | Compositions and methods of use for low-density lipoprotein-related protein 6 (LRP6) therapeutic antibodies |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
KR102240318B1 (en) | 2011-06-23 | 2021-04-15 | 아블린쓰 엔.브이. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
ES2813432T3 (en) | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Modified proteins and peptides |
EP3290442A1 (en) | 2011-11-04 | 2018-03-07 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs |
JP5949270B2 (en) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | Audio decoding apparatus, audio decoding method, and audio decoding computer program |
WO2014029752A1 (en) | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
CA3006235A1 (en) * | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
-
2016
- 2016-12-02 CA CA3006235A patent/CA3006235A1/en active Pending
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/en unknown
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/en not_active Withdrawn
- 2016-12-02 UA UAA201807120A patent/UA122079C2/en unknown
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 SI SI201630953T patent/SI3383425T1/en unknown
- 2016-12-02 ES ES16808971T patent/ES2821099T3/en active Active
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/en active Active
- 2016-12-02 EA EA201891331A patent/EA201891331A1/en unknown
- 2016-12-02 TW TW105139826A patent/TWI734719B/en active
- 2016-12-02 PT PT168089712T patent/PT3383425T/en unknown
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/en active
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/en active Active
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/en unknown
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/en active Application Filing
- 2016-12-02 KR KR1020187019053A patent/KR20180081825A/en not_active Application Discontinuation
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/en active Active
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/en unknown
- 2016-12-02 MX MX2018006760A patent/MX2018006760A/en unknown
- 2016-12-02 RS RS20201124A patent/RS60823B1/en unknown
- 2016-12-02 PL PL16808971T patent/PL3383425T3/en unknown
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 MA MA43368A patent/MA43368B1/en unknown
- 2016-12-02 BR BR112018010537-6A patent/BR112018010537A2/en active Search and Examination
- 2016-12-02 AR ARP160103720A patent/AR106949A1/en unknown
- 2016-12-02 MA MA054648A patent/MA54648A/en unknown
-
2018
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/en unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/en unknown
- 2018-06-01 PH PH12018501155A patent/PH12018501155A1/en unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/en unknown
- 2018-11-21 HK HK18114876.0A patent/HK1255725A1/en unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/en not_active Withdrawn
- 2020-09-24 HR HRP20201528TT patent/HRP20201528T1/en unknown
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181515A1 (en) | BIPARATOPIC POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS | |
CO2019012329A2 (en) | Polypeptides that antagonize wnt signaling in tumor cells | |
CY1122314T1 (en) | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | |
CY1122415T1 (en) | CYCLOPYLAMINES AS LSD1 INHIBITORS | |
ECSP17062716A (en) | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | |
CL2017001459A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
ECSP17083788A (en) | ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS AND OTHER CD38-POSITIVE HEMATOLOGIC MALIGNANT DISEASES | |
CR20150255A (en) | THYMPHENE FUSIONATED TRICICLIC DERIVATIVES AS JAK INHIBITORS | |
ECSP15043772A (en) | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | |
CR20160542A (en) | 1 H-PIRROLO [2,3-c] PIRIDIN-7 (6H) -ONAS YPIRAZOLO [3,4-c] PlRIDIN-7 (6H) -ONAS AS BET PROTEIN INHIBITORS | |
PE20170441A1 (en) | ANTIBODIES AGAINST THE GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND ITS USES | |
DK3286206T3 (en) | UNKNOWN HYBRID ACTRIIB-LIGAND-TRAP PROTEINS FOR THE TREATMENT OF MUSCLE WIND DISEASES | |
UY37018A (en) | PAD4 BICYCLIC INHIBITORS | |
EA201890185A1 (en) | METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID | |
EA201891376A1 (en) | BENZOTIOPHENE SELECTIVE BLOCKS OF ESTROGEN RECEPTORS | |
EA201692269A1 (en) | NEW COMPOSITIONS, THEIR USE AND METHODS OF OBTAINING | |
CL2018002810A1 (en) | Anti-complement factor bb antibodies and uses of these cross-reference. | |
UY33956A (en) | ANTIBODY OF THE HUMAN ANTITISULAR FACTOR AND ITS USES TO TREAT CANCER | |
CL2017001135A1 (en) | Enhanced antibodies against il-6 | |
CL2018001652A1 (en) | Compositions and methods to reduce tau expression | |
MX2015011518A (en) | Met-binding agents and uses thereof. | |
UY37980A (en) | NOVELTY COMPOUNDS TO TREAT PARASITIC DISEASES | |
CO2019012475A2 (en) | Novel fragrance compositions and products with mood-enhancing effects | |
EA201791814A1 (en) | IMIDAZOLYL TRYCYCLIC ENONS AS ANTIOXIDANT INFLAMMATION MODULATORS | |
BR112018068798A2 (en) | compositions and methods for treating parasitic diseases |